DOCSLIB.ORG

Insights Into Immunogenic Cell Death in Onco-Therapies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Insights Into Immunogenic Cell Death in Onco-Therapies cancers Review Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies Ángela-Patricia Hernández 1 , Pablo Juanes-Velasco 1 , Alicia Landeira-Viñuela 1, Halin Bareke 1,2, Enrique Montalvillo 1, Rafael Góngora 1 and Manuel Fuentes 1,3,* 1 Department of Medicine and General Cytometry Service-Nucleus, CIBERONC CB16/12/00400, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, Spain; [email protected] (Á.-P.H.); [email protected] (P.J.-V.); [email protected] (A.L.-V.); [email protected] (H.B.); [email protected] (E.M.); [email protected] (R.G.) 2 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Institute of Health Sciences, Marmara University, 34722 Istanbul, Turkey 3 Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, Spain * Correspondence: [email protected]; Tel.: +34-923-294-811 Simple Summary: Since the role of immune evasion was included as a hallmark in cancer, the idea of cancer as a single cell mass that replicate unlimitedly in isolation was dissolved. In this sense, cancer and tumorigenesis cannot be understood without taking into account the tumor microenvironment (TME) that plays a crucial role in drug resistance. Immune characteristics of TME can determine the success in treatment at the same time that antitumor therapies can reshape the immunity in TME. Here, we collect a variety of onco-therapies that have been demonstrated to induce an interesting Citation: Hernández, Á.-P.; immune response accompanying its pharmacological action that is named as “immunogenic cell Juanes-Velasco, P.; Landeira-Viñuela, death”. As this report shows, immunogenic cell death has been gaining importance in antitumor A.; Bareke, H.; Montalvillo, E.; therapy and should be studied in depth as well as taking into account other applications that may Góngora, R.; Fuentes, M. Restoring arise from this immune phenomenon. the Immunity in the Tumor Microenvironment: Insights into Abstract: Immunogenic cell death (ICD) elicited by cancer therapy reshapes the tumor immune Immunogenic Cell Death in Onco-Therapies. Cancers 2021, 13, microenvironment. A long-term adaptative immune response can be initiated by modulating cell 2821. https://doi.org/10.3390/ death by therapeutic approaches. Here, the major hallmarks of ICD, endoplasmic reticulum (ER) cancers13112821 stress, and damage-associated molecular patterns (DAMPs) are correlated with ICD inducers used in clinical practice to enhance antitumoral activity by suppressing tumor immune evasion. Approaches Academic Editor: Alberto Anel to monitoring the ICD triggered by antitumoral therapeutics in the tumor microenvironment (TME) and novel perspective in this immune system strategy are also reviewed to give an overview of the Received: 23 April 2021 relevance of ICD in cancer treatment. Accepted: 4 June 2021 Published: 5 June 2021 Keywords: immunogenic cell death; DAMPs; apoptosis; necroptosis; autophagy; tumor microenvi- ronment; natural products; chemotherapy; ICD inducers; immunotherapy Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affil- iations. 1. Introduction Since the establishment of tumorigenesis as a complex network of pathophysiological processes, cancer cell biology cannot be studied without taking into account the surround- ing elements (e.g., blood vessels, immune cells, and extracellular matrix). Tumor cells Copyright: © 2021 by the authors. have acquired mechanisms to hinder anti-tumor immunity. The tumor’s ability to evade Licensee MDPI, Basel, Switzerland. the immune system is one of the steps that have been considered necessary for tumor This article is an open access article establishment and has been included in multi-step processes that have been identified as distributed under the terms and conditions of the Creative Commons “hallmarks of cancer” proposed by Hanahan and Weinberg [1]. The role of immune evasion Attribution (CC BY) license (https:// was included as a hallmark when the idea of cancer as a single cell mass that replicates creativecommons.org/licenses/by/ unlimitedly in isolation was dissolved (Figure1). Rather, it was accepted that a set of 4.0/). normal cells that are recruited to the tumor or that are altered by the tumor to form the Cancers 2021, 13, 2821. https://doi.org/10.3390/cancers13112821 https://www.mdpi.com/journal/cancers Cancers 2021, 13, x 2 of 31 Cancers 2021, 13, 2821 2 of 30 that a set of normal cells that are recruited to the tumor or that are altered by the tumor to form the tumor-associated stroma, were pivotal for tumor establishment and progression. tumor-associated stroma, were pivotal for tumor establishment and progression. Therefore, Therefore, the cancer cell and tumorigenesis cannot be understood without taking into the cancer cell and tumorigenesis cannot be understood without taking into account the account the tumor microenvironment (TME) [2]. In-depth understanding of molecular signalingtumor and microenvironment extracellular interactions (TME) invo [2].lved In-depth in these understanding processes allows of the molecular develop- signaling and ment extracellularof novel therapies interactions that include involved conventional in these intracellular processes targets allows as the well development as novel of novel approachestherapies to modulate that include the TME. conventional intracellular targets as well as novel approaches to modulate the TME. Figure 1. The immune system within the cancer hallmarks plays a pivotal role in understanding of the TME. Figure 1. The immune system within the cancer hallmarks plays a pivotal role in understanding Treatment resistance remainsof the an TME. important challenge in cancer therapy. Drug resis- tance can be intrinsic due to the presence of mutations that inactivate its potential molecular Treatment resistance remains an important challenge in cancer therapy. Drug re- targets [3]. However, extrinsic resistance of the tumor cells can be promoted by the tumor sistance can be intrinsic due to the presence of mutations that inactivate its potential mo- surrounding. As stated before, tumors are surrounded by a high density of elements lecular targets [3]. However, extrinsic resistance of the tumor cells can be promoted by the tumorsuch surrounding. as extracellular As stated matrix, before, aberrant tumors are vasculature, surrounded and by stromaa high density cells. Withinof ele- this cellular mentscomponent such as extracellular surrounding matrix, the aberrant tumor, vasculature, tumor-infiltrating and stroma cells cells. are Within of special this cel- interest because lular componentof their contradictory surrounding roles the tumor, in immunomodulation tumor-infiltrating cells of tumorare of special progression. interest Whilebe- some cell causepopulations of their contradictory boost tumorigenic roles in immu factors,nomodulation others can of restore tumor immunosurveillance progression. While against the some tumors.cell populations In TME, boost the balancetumorigenic is tilted factors, towards others the can activation restore immunosurveillance of tumor survival-promoting againstelements the tumors. that In enable TME, the tumor balance immune is tilted evasion towards [ the4]. Therefore,activation of therapies tumor survival- that target the im- promotingmunosuppressive elements that enable environment tumor immune in the TMEevasion has [4]. the Therefore, potential therapies to unlock that the tar- power of the get theimmune immunosuppressive system against environment tumor cells. in the TME has the potential to unlock the power of the immune system against tumor cells. 2. Cancer Immunoediting, TME, and Immunogenic Cell Death 2. Cancer Immunoediting, TME, and Immunogenic Cell Death Interactions between the immune system and the tumor, even before the onset of the Interactionsclinical signs between of a tumor, the immune are well system characterized. and the tumor, This even process before encompasses the onset of the different steps clinicalthat signs have of a been tumor, termed are well jointly characteri as immunoeditingzed. This process [ 5encompasses]. Cancer immunoediting different steps defines the that have been termed jointly as immunoediting [5]. Cancer immunoediting defines the interaction between immune cells and tumor cells that can result in either elimination of interaction between immune cells and tumor cells that can result in either elimination of the tumor, an equilibrium state where the tumor is latent or generation of tumor cell popu- the tumor, an equilibrium state where the tumor is latent or generation of tumor cell pop- ulationslations that are that able are to able survive to survive in immunoco in immunocompetentmpetent hosts [6]. First, hosts pre-tumoral [6]. First, pre-tumoralchanges changes are detectedare detected and neutralized and neutralized by the innate by the an innated adaptative and adaptative immune system immune in the system step in the step namednamed “elimination”. “elimination”. In the “equilibrium” In the “equilibrium” phase, the phase, tumor is the not tumor completely is not eliminated; completely eliminated; however,however, it is kept it is under kept undercontrol control by the byimmune the immune system so system that it so doesn’t that it become doesn’t clini- become clinically cally detectable. Finally, Finally, tumors tumors develop develop an editing an editing process process where where immunogenic immunogenic tumor tumor cells
Load more

Recommended publications
  • Formulary Adherence Checklist
    NICE Technology Appraisals About Medicines: Formulary Adherence Checklist This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS. Last updated 18-Jun-19 Technology appraisal Date of TA Availability of medicine for NHS patients with this medical condition, as indicated by (TA) Release NICE Adherence of local formulary to NICE Titles are hyperlinks to Yes N/A Date of local Date of local Time to full guidance (mark 'x' if (mark 'x' if decision decision implement applicable) applicable) Due (90 days) Made (days) 2018-19 TA517 Avelumab for Avelumab for treating metastatic Merkel cell carcinoma. 1 treating metastatic 11/04/2018 Evidence-based recommendations on avelumab (Bavencio) for treating metastatic X 10/07/2018 17/12/2018 250 Merkel cell carcinoma (secondary) Merkel cell carcinoma in adults. TA518 Tocilizumab for Tocilizumab for treating giant cell arteritis. 1 treating giant cell 18/04/2018 Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell X 17/07/2018 16/07/2018 89 arteritis arteritis in adults. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after TA519 Pembrolizumab platinum-containing chemotherapy. for treating locally Evidence-based recommendations on pembrolizumab (Keytruda) for previously advanced or metastatic treated locally advanced or metastatic urothelial carcinoma in adults. 1 urothelial carcinoma 25/04/2018 X 24/07/2018 04/05/2018 9 after platinum- containing chemotherapy TA520 - Atezolizumab Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced for treating locally or metastatic non-small-cell lung cancer after chemotherapy in adults.
    [Show full text]
  • Toxicogenomics Article
    Toxicogenomics Article Discovery of Novel Biomarkers by Microarray Analysis of Peripheral Blood Mononuclear Cell Gene Expression in Benzene-Exposed Workers Matthew S. Forrest,1 Qing Lan,2 Alan E. Hubbard,1 Luoping Zhang,1 Roel Vermeulen,2 Xin Zhao,1 Guilan Li,3 Yen-Ying Wu,1 Min Shen,2 Songnian Yin,3 Stephen J. Chanock,2 Nathaniel Rothman,2 and Martyn T. Smith1 1School of Public Health, University of California, Berkeley, California, USA; 2Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA; 3National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing, China were then ranked and selected for further exam- Benzene is an industrial chemical and component of gasoline that is an established cause of ination using several forms of statistical analysis. leukemia. To better understand the risk benzene poses, we examined the effect of benzene expo- We also specifically examined the expression sure on peripheral blood mononuclear cell (PBMC) gene expression in a population of shoe- of all cytokine genes on the array under the factory workers with well-characterized occupational exposures using microarrays and real-time a priori hypothesis that these key genes polymerase chain reaction (PCR). PBMC RNA was stabilized in the field and analyzed using a involved in immune function are likely to be comprehensive human array, the U133A/B Affymetrix GeneChip set. A matched analysis of six altered by benzene exposure (Aoyama 1986). exposed–control pairs was performed. A combination of robust multiarray analysis and ordering We then attempted to confirm the array find- of genes using paired t-statistics, along with bootstrapping to control for a 5% familywise error ings for the leading differentially expressed rate, was used to identify differentially expressed genes in a global analysis.
    [Show full text]
  • Nanosecond-Pulsed DBD Plasma-Generated Reactive Oxygen Species Trigger Immunogenic Cell Death in A549 Lung Carcinoma Cells Through Intracellular Oxidative Stress
    International Journal of Molecular Sciences Article Nanosecond-Pulsed DBD Plasma-Generated Reactive Oxygen Species Trigger Immunogenic Cell Death in A549 Lung Carcinoma Cells through Intracellular Oxidative Stress Abraham Lin 1, Billy Truong 1, Sohil Patel 1, Nagendra Kaushik 2, Eun Ha Choi 2, Gregory Fridman 1, Alexander Fridman 1 and Vandana Miller 1,* 1 C. & J. Nyheim Plasma Institute, Drexel University, Philadelphia, PA 19104, USA; [email protected] (A.L.); [email protected] (B.T.); [email protected] (S.P.); [email protected] (G.F.); [email protected] (A.F.) 2 Plasma Bioscience Research Center, Kwangwoon University, Seoul 139791, Korea; [email protected] (N.K.); [email protected] (E.H.C.) * Correspondence: [email protected]; Tel.: +1-215-571-4074 Academic Editor: Hsueh-Wei Chang Received: 1 March 2017; Accepted: 28 April 2017; Published: 3 May 2017 Abstract: A novel application for non-thermal plasma is the induction of immunogenic cancer cell death for cancer immunotherapy. Cells undergoing immunogenic death emit danger signals which facilitate anti-tumor immune responses. Although pathways leading to immunogenic cell death are not fully understood; oxidative stress is considered to be part of the underlying mechanism. Here; we studied the interaction between dielectric barrier discharge plasma and cancer cells for oxidative stress-mediated immunogenic cell death. We assessed changes to the intracellular oxidative environment after plasma treatment and correlated it to emission of two danger signals: surface-exposed calreticulin and secreted adenosine triphosphate. Plasma-generated reactive oxygen and charged species were recognized as the major effectors of immunogenic cell death. Chemical attenuators of intracellular reactive oxygen species successfully abrogated oxidative stress following plasma treatment and modulated the emission of surface-exposed calreticulin.
    [Show full text]
  • EAU-EANM-ESUR-ESTRO-SIOG Guidelines on Prostate Cancer 2019
    EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer N. Mottet (Chair), R.C.N. van den Bergh, E. Briers (Patient Representative), P. Cornford (Vice-chair), M. De Santis, S. Fanti, S. Gillessen, J. Grummet, A.M. Henry, T.B. Lam, M.D. Mason, T.H. van der Kwast, H.G. van der Poel, O. Rouvière, D. Tilki, T. Wiegel Guidelines Associates: T. Van den Broeck, M. Cumberbatch, N. Fossati, T. Gross, M. Lardas, M. Liew, L. Moris, I.G. Schoots, P-P.M. Willemse © European Association of Urology 2019 TABLE OF CONTENTS PAGE 1. INTRODUCTION 9 1.1 Aims and scope 9 1.2 Panel composition 9 1.2.1 Acknowledgement 9 1.3 Available publications 9 1.4 Publication history and summary of changes 9 1.4.1 Publication history 9 1.4.2 Summary of changes 9 2. METHODS 12 2.1 Data identification 12 2.2 Review 13 2.3 Future goals 13 3. EPIDEMIOLOGY AND AETIOLOGY 13 3.1 Epidemiology 13 3.2 Aetiology 14 3.2.1 Family history / genetics 14 3.2.2 Risk factors 14 3.2.2.1 Metabolic syndrome 14 3.2.2.1.1 Diabetes/metformin 14 3.2.2.1.2 Cholesterol/statins 14 3.2.2.1.3 Obesity 14 3.2.2.2 Dietary factors 14 3.2.2.3 Hormonally active medication 15 3.2.2.3.1 5-alpha-reductase inhibitors 15 3.2.2.3.2 Testosterone 15 3.2.2.4 Other potential risk factors 15 3.2.3 Summary of evidence and guidelines for epidemiology and aetiology 16 4.
    [Show full text]
  • Killing Cancer Cells, Twice with One Shot
    Cell Death and Differentiation (2014) 21, 1–2 & 2014 Macmillan Publishers Limited All rights reserved 1350-9047/14 www.nature.com/cdd Editorial Killing cancer cells, twice with one shot ME Bianchi*,1 Cell Death and Differentiation (2014) 21, 1–2; doi:10.1038/cdd.2013.147 I can still remember lecturing that chemotherapy and radio- shows that transglutaminase (TG) 2, a protein with several therapy are effective because they kill cancer cells. That was complex activities, can prevent calreticulin exposure on the simple enough, and when I wanted to make it a bit more cell surface, and therefore TG2-overexpressing cancer cells complex, I ventured into explaining how they mainly killed can escape activation of the immune system.9 cancer cells because they divided much more than other cells, Curiously, calreticulin is also surface exposed by spermato- and how the killing involved apoptosis. Things have moved on zoa, both in mammals and nematodes, to facilitate fertiliza- quite a bit since then. Evidence accumulated in the past few tion. Following the phylogenetic trail to its widest extent, years indicates that some anti-cancer drugs do not kill cancer Sukkurwala et al.10 show that yeast calreticulin, CNE1 protein, cells, but merely push them into senescence, some do kill is surface exposed following ER stress, and facilitates yeast cells but not via apoptosis, and some do kill cells via apoptosis mating too.10 The binding of yeast pheromone a-factor to its G but that is not the main ingredient in their efficacy. protein-coupled receptor (GPCR) induces CNE1 surface The main theme of this issue is that dying cancer cells presentation.
    [Show full text]
  • CXCL16 Suppresses Liver Metastasis of Colorectal Cancer by Promoting
    Kee et al. BMC Cancer 2014, 14:949 http://www.biomedcentral.com/1471-2407/14/949 RESEARCH ARTICLE Open Access CXCL16 suppresses liver metastasis of colorectal cancer by promoting TNF-α-induced apoptosis by tumor-associated macrophages Ji-Ye Kee1†, Aya Ito1,2†, Shozo Hojo3, Isaya Hashimoto3, Yoshiko Igarashi2, Koichi Tsuneyama4, Kazuhiro Tsukada3, Tatsuro Irimura5, Naotoshi Shibahara2, Ichiro Takasaki9, Akiko Inujima2, Takashi Nakayama6, Osamu Yoshie7, Hiroaki Sakurai8, Ikuo Saiki1 and Keiichi Koizumi2*† Abstract Background: Inhibition of metastasis through upregulation of immune surveillance is a major purpose of chemokine gene therapy. In this study, we focused on a membrane-bound chemokine CXCL16, which has shown a correlation with a good prognosis for colorectal cancer (CRC) patients. Methods: We generated a CXCL16-expressing metastatic CRC cell line and identified changes in TNF and apoptosis- related factors. To investigate the effect of CXCL16 on colorectal liver metastasis, we injected SL4-Cont and SL4-CXCL16 cells into intraportal vein in C57BL/6 mice and evaluated the metastasis. Moreover, we analyzed metastatic liver tissues using flow cytometry whether CXCL16 expression regulates the infiltration of M1 macrophages. Results: CXCL16 expression enhanced TNF-α-induced apoptosis through activation of PARP and the caspase-3- mediated apoptotic pathway and through inactivation of the NF-κB-mediated survival pathway. Several genes were changed by CXCL16 expression, but we focused on IRF8, which is a regulator of apoptosis and the metastatic phenotype. We confirmed CXCL16 expression in SL4-CXCL16 cells and the correlation between CXCL16 and IRF8. Silencing of IRF8 significantly decreased TNF-α-induced apoptosis. Liver metastasis of SL4-CXCL16 cells was also inhibited by TNF-α-induced apoptosis through the induction of M1 macrophages, which released TNF-α.
    [Show full text]
  • CXC Chemokine Ligand 16 Regulates the Cell Surface Expression of 10
    A Disintegrin and Metalloproteinase 10-Mediated Cleavage and Shedding Regulates the Cell Surface Expression of CXC Chemokine Ligand 16 This information is current as of October 2, 2021. Peter J. Gough, Kyle J. Garton, Paul T. Wille, Marcin Rychlewski, Peter J. Dempsey and Elaine W. Raines J Immunol 2004; 172:3678-3685; ; doi: 10.4049/jimmunol.172.6.3678 http://www.jimmunol.org/content/172/6/3678 Downloaded from References This article cites 35 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/172/6/3678.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology A Disintegrin and Metalloproteinase 10-Mediated Cleavage and Shedding Regulates the Cell Surface Expression of CXC Chemokine Ligand 16 Peter J. Gough,2* Kyle J. Garton,* Paul T.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Stress-Induced Inflammation Evoked by Immunogenic Cell Death Is
    www.nature.com/cdd ARTICLE OPEN Stress-induced inflammation evoked by immunogenic cell death is blunted by the IRE1α kinase inhibitor KIRA6 through HSP60 targeting Nicole Rufo1,2, Dimitris Korovesis3,Sofie Van Eygen1,2, Rita Derua4, Abhishek D. Garg 1, Francesca Finotello5, Monica Vara-Perez1,2, ž 6,7 2,8 9 7,10 11 6 Jan Ro anc , Michael Dewaele , Peter A. de Witte , Leonidas G. Alexopoulos✉ , Sophie Janssens , Lasse Sinkkonen , Thomas Sauter6, Steven H. L. Verhelst 3,12 and Patrizia Agostinis 1,2 © The Author(s) 2021 Mounting evidence indicates that immunogenic therapies engaging the unfolded protein response (UPR) following endoplasmic reticulum (ER) stress favor proficient cancer cell-immune interactions, by stimulating the release of immunomodulatory/ proinflammatory factors by stressed or dying cancer cells. UPR-driven transcription of proinflammatory cytokines/chemokines exert beneficial or detrimental effects on tumor growth and antitumor immunity, but the cell-autonomous machinery governing the cancer cell inflammatory output in response to immunogenic therapies remains poorly defined. Here, we profiled the transcriptome of cancer cells responding to immunogenic or weakly immunogenic treatments. Bioinformatics-driven pathway analysis indicated that immunogenic treatments instigated a NF-κB/AP-1-inflammatory stress response, which dissociated from both cell death and UPR. This stress-induced inflammation was specifically abolished by the IRE1α-kinase inhibitor KIRA6. Supernatants from immunogenic chemotherapy and KIRA6 co-treated cancer cells were deprived of proinflammatory/chemoattractant factors and failed to mobilize neutrophils and induce dendritic cell maturation. Furthermore, KIRA6 significantly reduced the in vivo vaccination potential of dying cancer cells responding to immunogenic chemotherapy. Mechanistically, we found that the anti-inflammatory effect of KIRA6 was still effective in IRE1α-deficient cells, indicating a hitherto unknown off-target effector of this IRE1α-kinase inhibitor.
    [Show full text]
  • Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma Tuba N
    Published OnlineFirst November 10, 2017; DOI: 10.1158/1078-0432.CCR-17-2267 Review Clinical Cancer Research Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma Tuba N. Gide1,2, James S. Wilmott1,2, Richard A. Scolyer1,2,3, and Georgina V. Long1,2,4,5 Abstract Immune checkpoint inhibitors have revolutionized the treat- involves various components of the cancer immune cycle, and ment of patients with advanced-stage metastatic melanoma, as interactions between multiple signaling molecules and path- well as patients with many other solid cancers, yielding long- ways. Due to this complexity, current knowledge on resistance lasting responses and improved survival. However, a subset of mechanisms is still incomplete. Overcoming therapy resistance patientswhoinitiallyrespondtoimmunotherapy,laterrelapse requires a thorough understanding of the mechanisms under- and develop therapy resistance (termed "acquired resistance"), lying immune evasion by tumors. In this review, we explore the whereas others do not respond at all (termed "primary resis- mechanisms of primary and acquired resistance to immuno- tance"). Primary and acquired resistance are key clinical barriers therapy in melanoma and detail potential therapeutic strategies to further improving outcomes of patients with metastatic to prevent and overcome them. Clin Cancer Res; 24(6); 1–11. Ó2017 melanoma, and the known mechanisms underlying each AACR. Introduction Drugs targeting the programmed cell death receptor 1 (PD-1, PDCD1) showed a further increase in response rates, PFS (2), and Immune checkpoint inhibitors have revolutionized the treat- OS (14–16) compared with anti–CTLA-4 blockade. PD-1 is also ment of advanced melanoma (1–5) and have significant clinical expressed on the surface of activated T cells and binds to the activity across an increasing range of many other solid malignan- programmed cell death ligand 1 (PD-L1, CD274) to negatively cies, including non–small cell lung cancer (6, 7), renal cell regulate T-cell activation and differentiation.
    [Show full text]
  • Pathogen Response-Like Recruitment and Activation of Neutrophils by Sterile Immunogenic Dying Cells Drives Neutrophil-Mediated Residual Cell Killing
    Cell Death and Differentiation (2017) 24, 832–843 & 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 1350-9047/17 www.nature.com/cdd Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing Abhishek D Garg*,1,2, Lien Vandenberk3, Shentong Fang4, Tekele Fasche4, Sofie Van Eygen1, Jan Maes5, Matthias Van Woensel6,7, Carolien Koks3, Niels Vanthillo5, Norbert Graf8, Peter de Witte5, Stefaan Van Gool9, Petri Salven4 and Patrizia Agostinis*,1 Innate immune sensing of dying cells is modulated by several signals. Inflammatory chemokines-guided early recruitment, and pathogen-associated molecular patterns-triggered activation, of major anti-pathogenic innate immune cells like neutrophils distinguishes pathogen-infected stressed/dying cells from sterile dying cells. However, whether certain sterile dying cells stimulate innate immunity by partially mimicking pathogen response-like recruitment/activation of neutrophils remains poorly understood. We reveal that sterile immunogenic dying cancer cells trigger (a cell autonomous) pathogen response-like chemokine (PARC) signature, hallmarked by co-release of CXCL1, CCL2 and CXCL10 (similar to cells infected with bacteria or viruses). This PARC signature recruits preferentially neutrophils as first innate immune responders in vivo (in a cross-species, evolutionarily conserved manner; in mice and zebrafish). Furthermore, key danger signals emanating from these dying cells, that is, surface calreticulin, ATP and nucleic acids stimulate phagocytosis, purinergic receptors and toll-like receptors (TLR) i.e. TLR7/8/9-MyD88 signaling on neutrophil level, respectively. Engagement of purinergic receptors and TLR7/8/9-MyD88 signaling evokes neutrophil activation, which culminates into H2O2 and NO-driven respiratory burst-mediated killing of viable residual cancer cells.
    [Show full text]
  • Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: an Update
    biomedicines Review Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update Sonja Vukadin 1,2, Farah Khaznadar 1, Tomislav Kizivat 3,4, Aleksandar Vcev 5,6,7 and Martina Smolic 1,2,* 1 Department of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia; [email protected] (S.V.); [email protected] (F.K.) 2 Department of Pharmacology, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia 3 Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Osijek, 31000 Osijek, Croatia; [email protected] 4 Department of Nuclear Medicine and Oncology, Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia 5 Department of Pathophysiology, Physiology and Immunology, Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia; [email protected] 6 Department of Pathophysiology, Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia 7 Department of Internal Medicine, University Hospital Osijek, 31000 Osijek, Croatia * Correspondence: [email protected] Abstract: Over the past decade, immune checkpoint inhibitors (ICI) have revolutionized the treatment of advanced melanoma and ensured significant improvement in overall survival versus chemother- apy. ICI or targeted therapy are now the first line treatment in advanced melanoma, depending on the tumor v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutational status. While these Citation: Vukadin, S.; Khaznadar, F.; new approaches have changed the outcomes for many patients, a significant proportion of them still Kizivat, T.; Vcev, A.; Smolic, M.
    [Show full text]